1581734-83-9

Upstream product

• 1581734-79-3 (2R)-5,5,5-trifluoro-2-hydroxypentanoic acid 
• 1581734-80-6 benzyl (2R)-5,5,5-trifluoro-2-hydroxypentanoate 
• 1581734-81-7 benzyl (2R)-5,5,5-trifluoro-2-{[(trifluoromethyl)sulfonyl]oxy}pentanoate 
• 16537-09-0 t-butyl phenylacetate 
• 122565-29-1 (2R)-2-amino-5,5,5-trifluoropentanoic acid 
• 103-82-2 phenylacetic acid 

Downstream Products

• 1584149-67-6 (2R,3R)-N-((3S)-1-(3-cyanophenyl)-6-(difluoromethyl)-4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-phenyl-2-(3,3,3-trifluoropropyl)succinamide 
• 1584150-55-9 (2R,3R)-3-(((S)-1-(3-cyanophenyl)-6-(difluoromethyl)-4-oxo-2,3,4,5-tetrahydro-1H-benzo-[b][1,4]-diazepin-3-yl)carbamoyl)-6,6,6-trifluoro-2-phenylhexanoic acid 
• 1584150-54-8 (2R,3R)-tert-butyl 3-(((S)-1-(3-cyanophenyl)-6-(difluoromethyl)-4-oxo-2,3,4,5-tetrahydro-1H-benzo-[b][1,4]-diazepin-3-yl)carbamoyl)-6,6,6-trifluoro-2-phenylhexanoate 

Relevant academic research and scientific papers

TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS

Disclosed are compounds of Formula (I), wherein: X is O or -NR3; R1 is -CH2CH2CH3, -CH2CF3, -CH2CH2CF3, -CH2CF2CH3, -CH2CH2CH2CF3, -CH2CH2CF2CH3, -CH2CH(CH3)CF3, -CH2CH2CH2F, or CH2(cyclopropyl); R2 is -CH2CH2CH3, -CH2CF3, -CH2CH2CF3, -CH2CF2CH3, -CH2CH2CH2CF3, -CH2CH2CH2F, -CH2CH(CH3)CF3, CH2CH2CF2CH3, -CH2(cyclopropyl), -CH(CH3)(cyclopropyl), phenyl, fluorophenyl, chlorophenyl, trifluorophenyl, methylisoxazolyl, pyridinyl, formula (i), formula (ii), formula (iii), formula (iv) or formula (v); Ring A is phenyl or pyridinyl; and R3, Ra, Rb, Rc, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

SUBSTITUTED 1,5-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I): wherein: R1 is CH2CH2CF3; R2 is CH2CH2CF3, CH2(cyclopropyl), or phenyl; R3 is H or CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.